Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization

Ioannis D Ladas, Marilita M Moschos, Thanos D Papakostas, Athanasios I Kotsolis, Ilias Georgalas, Michail ApostolopoulosDepartment of Ophthalmology, &ldquo;G. Gennimatas&rdquo; Hospital of Athens, University of Athens, Athens, GreecePurpose: The purpose of this observational case rep...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ioannis D Ladas, Marilita M Moschos, Thanos D Papakostas, Athanasios I Kotsolis, Ilias Georgalas, Michail Apostolopoulos
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/83032938609349a3850bede93d83ba18
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83032938609349a3850bede93d83ba18
record_format	dspace
spelling	oai:doaj.org-article:83032938609349a3850bede93d83ba182021-12-02T06:39:33ZSkin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization1177-54671177-5483https://doaj.org/article/83032938609349a3850bede93d83ba182008-12-01T00:00:00Zhttp://www.dovepress.com/skin-rash-associated-with-intravitreal-bevacizumab-in-a-patient-with-m-a2734https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Ioannis D Ladas, Marilita M Moschos, Thanos D Papakostas, Athanasios I Kotsolis, Ilias Georgalas, Michail ApostolopoulosDepartment of Ophthalmology, &ldquo;G. Gennimatas&rdquo; Hospital of Athens, University of Athens, Athens, GreecePurpose: The purpose of this observational case report is to describe a case of skin rash after intravitreal use of bevacizumab.Methods: A 50-year-old man with choroidal neovascularization in the right eye due to age-related macular degeneration was treated with three intravitreal injections of bevacizumab.Results: Twelve days after the first injection, the patient developed a maculopapular rash on his forehead and on both temporal regions around his eyes. The rash disappeared eight days after treatment with topical corticosteroids. A skin rash with the same distribution reappeared 14 days after the second and 10 days after the third injection. Similarly, it disappeared five and seven days after the use of the same treatment. The follow-up period was 15 months after the third injection. During the follow-up period the rash did not reappear.Conclusion: This case report may initiate further investigation of similar cases to support this observation, as there are a lack of reports of skin rash after intravitreal administration of bevacizumab.Keywords: skin rash, bevacizumab, age-related macular degeneration Ioannis D LadasMarilita M MoschosThanos D PapakostasAthanasios I KotsolisIlias GeorgalasMichail ApostolopoulosDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 129-131 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Ioannis D Ladas Marilita M Moschos Thanos D Papakostas Athanasios I Kotsolis Ilias Georgalas Michail Apostolopoulos Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
description	Ioannis D Ladas, Marilita M Moschos, Thanos D Papakostas, Athanasios I Kotsolis, Ilias Georgalas, Michail ApostolopoulosDepartment of Ophthalmology, &ldquo;G. Gennimatas&rdquo; Hospital of Athens, University of Athens, Athens, GreecePurpose: The purpose of this observational case report is to describe a case of skin rash after intravitreal use of bevacizumab.Methods: A 50-year-old man with choroidal neovascularization in the right eye due to age-related macular degeneration was treated with three intravitreal injections of bevacizumab.Results: Twelve days after the first injection, the patient developed a maculopapular rash on his forehead and on both temporal regions around his eyes. The rash disappeared eight days after treatment with topical corticosteroids. A skin rash with the same distribution reappeared 14 days after the second and 10 days after the third injection. Similarly, it disappeared five and seven days after the use of the same treatment. The follow-up period was 15 months after the third injection. During the follow-up period the rash did not reappear.Conclusion: This case report may initiate further investigation of similar cases to support this observation, as there are a lack of reports of skin rash after intravitreal administration of bevacizumab.Keywords: skin rash, bevacizumab, age-related macular degeneration
format	article
author	Ioannis D Ladas Marilita M Moschos Thanos D Papakostas Athanasios I Kotsolis Ilias Georgalas Michail Apostolopoulos
author_facet	Ioannis D Ladas Marilita M Moschos Thanos D Papakostas Athanasios I Kotsolis Ilias Georgalas Michail Apostolopoulos
author_sort	Ioannis D Ladas
title	Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
title_short	Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
title_full	Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
title_fullStr	Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
title_full_unstemmed	Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
title_sort	skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/83032938609349a3850bede93d83ba18
work_keys_str_mv	AT ioannisdladas skinrashassociatedwithintravitrealbevacizumabinapatientwithmacularchoroidalneovascularization AT marilitammoschos skinrashassociatedwithintravitrealbevacizumabinapatientwithmacularchoroidalneovascularization AT thanosdpapakostas skinrashassociatedwithintravitrealbevacizumabinapatientwithmacularchoroidalneovascularization AT athanasiosikotsolis skinrashassociatedwithintravitrealbevacizumabinapatientwithmacularchoroidalneovascularization AT iliasgeorgalas skinrashassociatedwithintravitrealbevacizumabinapatientwithmacularchoroidalneovascularization AT michailapostolopoulos skinrashassociatedwithintravitrealbevacizumabinapatientwithmacularchoroidalneovascularization
_version_	1718399820901646336

Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization

Ejemplares similares